Inova Software Secures Additional Funding from Its Founders and NextStage AM to Support Its Strong Growth
In a financial deal of 6M€, NextStage AM takes a stake in Inova Software, a SaaS partnering platform for pharmaceutical and biotechnology companies, to further boost its growth.
Inova Software develops a SaaS partnering platform that facilitates collaborations between pharmaceutical and biotechnology companies. Inova Software’s solutions are used by over 120 companies, including half of the top 50 pharmaceutical companies, such as Roche, Novartis, Lilly and Bayer, to manage their external partnerships and accelerate their therapeutic advances.
The life sciences industry is undergoing a strong push towards partnering, driven by their need to innovate. Wanting to capitalize on this opportunity for growth, Inova Software is welcoming NextStage AM as a new shareholder. Inova Software’s Annual Recurrent Revenue has grown 30% year to year over the past 3 years and is expected to exceed 6 million euros this year. With this new financing, Inova Software anticipates even faster growth through:
- Inova Partnering Platform , covering the entire partnering lifecycle: Widely used by the business development and alliance management teams, Inova’s partnering platform is being adopted by more departments, such as R&D, M&A and manufacturing. These departments are all increasing their activities with external partners.
- Inova One-on-One Partnering, the digital networking solution for conferences: Since 2015, the Biotechnology Innovation Organization (BIO) and Inova have facilitated exchanges between life science companies during the industry’s biggest conferences. In 2018, for example, this solution enabled over 45,000 business meetings to be organized at BIO’s annual convention in Boston, USA. Based on its success, more and more life science events are adopting Inova’s networking solution.
By teaming up with NextStage AM, Inova Software will unleash its ability to innovate, reinforce its marketing investments, and execute acquisitions. Inova Software has offices in Lyon, New York and Tokyo. The company currently employs 50 people and plans to recruit an additional 15 employees in 2019. Inova Software generates over 90% of its turnover outside of France (including 45% in the United States) and expects to see its recurring revenue grow 40% in 2019.
“NextStage AM is a great fit for Inova. We were attracted by their strong entrepreneur/investor culture and enthusiasm for our ambitious, groundbreaking projects,” explained Gilles Toulemonde, CEO and co-founder of Inova Software.
“Inova Software manages to be both a leading player and a disruptive one in an industry that is undergoing an enormous amount of upheaval. This industry is reinventing itself and Inova Software has everything it takes to grow and become a strategic partner of top biopharma companies. We are proud to be able to accompany Inova over the long term,” added Nicolas de Saint Etienne, Partner, NextStage AM.
Inova provides a cloud-based software and services for life sciences companies to better manage their partnering lifecycle. By using Inova our clients manage their biopharma opportunities more efficiently. They find all their partnering information in one place, track their deals and alliances easily and report on their pipeline and activities in seconds.
We have also developed strategic partnerships that make data from the 20 biggest biopharma events automatically available in Inova, providing our users with always up-to-date company and contact information. Over 120 life science companies, including 50% of the top 50 pharmaceutical companies and many midsize pharma and biotechs already use Inova. We are headquartered in Lyon, France, and also operate offices in New York and Tokyo. For more information, visit www.inova-software.com
Based in Paris, NextStage AM is a leading growth equity firm. NextStage AM invests in a limited number of innovative French and European medium-sized businesses, bringing an entrepreneur/investor expertise and significant operational and international experience. NextStage AM provides these companies with the means to accelerate their development and their ability to innovate in order to become champions of their industry, in France and globally, through organic and/or external growth. For more information, visit www.nextstage.com
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54 | Pressemelding
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr
Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00 | Pressemelding
Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third
Tradeshift Announces Q3 2018 Results19.10.2018 11:00 | Pressemelding
Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between